Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. August 2019 06:00 ET | Quelle: Amicus Therapeutics, Inc.

Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease

Study Shows Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment...
15. September 2016 08:37 ET | Quelle: BioMarin Pharmaceutical Inc.

BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease

SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) validated the Marketing Authorization...
08. September 2016 04:30 ET | Quelle: BioMarin Pharmaceutical Inc.

BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting

SAN RAFAEL, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that two oral and 16 poster presentations related to the company’s products and...
03. Mai 2016 08:25 ET | Quelle: BioMarin Pharmaceutical Inc.

BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease

EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016 Company Seeking Priority Review in the U.S. SAN RAFAEL, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- BioMarin...
02. März 2016 19:05 ET | Quelle: BioMarin Pharmaceutical Inc.

BioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016

80% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001) Company Plans to Submit Marketing Applications Starting Mid-Year 2016 SAN RAFAEL, Calif., March...
29. Februar 2016 08:25 ET | Quelle: BioMarin Pharmaceutical Inc.

BioMarin Announces 21 Presentations at 12th Annual WORLDSymposium™ 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 Poster

SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present data in six oral and 15 poster presentations at the...